文献速递呼吸衰竭与机械通气

经鼻高流量氧疗与无创通气治疗慢性阻塞性肺疾病急性加重合并急性中度高碳酸血症性呼吸衰竭:随机对照非劣效性试验

High flow nasal cannula oxygen therapy versus non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: a randomized controlled non-inferiority trial.
PubMed 文献 · Crit Care · 2024-07-18
一句话结论在AECOPD合并急性中度高碳酸血症性呼吸衰竭患者中,HFNC作为初始呼吸支持的治疗失败率高于NIV,未达到非劣效。

该随机、开放标签、非劣效性试验在两家ICU纳入225例AECOPD合并急性中度高碳酸血症性呼吸衰竭患者(pH 7.25-7.35,PaCO2≥50 mmHg),比较HFNC与NIV作为初始呼吸支持的治疗失败率。HFNC组失败率25.7%,NIV组14.3%,风险差11.38%(95%CI 0.25-21.20,P=0.033),超过9%的非劣效界值;符合方案分析结果一致(25.5% vs 13.8%,风险差11.69%,95%CI 0.48-22.60)。HFNC组插管率高于NIV组(14.2% vs 5.4%,P=0.026)。结论提示HFNC未显示非劣于NIV,作为初始呼吸支持治疗失败率更高。

要点

  • AECOPD合并急性中度高碳酸血症性呼吸衰竭(pH 7.25-7.35,PaCO2≥50 mmHg)患者,HFNC作为初始呼吸支持的治疗失败率25.7%,高于NIV的14.3%,风险差11.38%(95%CI 0.25-21.20,P=0.033),超过9%非劣效界值。
  • HFNC组插管率14.2%,高于NIV组的5.4%(P=0.026)。
  • 符合方案分析中,HFNC组治疗失败25.5%(28/110),NIV组13.8%(15/109),风险差11.69%(95%CI 0.48-22.60)。
  • 两组治疗切换率、ICU住院时间、住院时间及28天死亡率差异均无统计学意义(均P>0.05)。

适用人群与场景

  • 纳入AECOPD合并急性中度高碳酸血症性呼吸衰竭患者,基线动脉血气pH 7.25-7.35且PaCO2≥50 mmHg,收治于两家ICU。

诊断标准与关键阈值

  • 急性中度高碳酸血症性呼吸衰竭诊断标准:动脉血气pH 7.25-7.35且PaCO2≥50 mmHg。
  • 治疗失败定义:气管插管或切换至另一研究治疗模式。
  • 非劣效界值:9%。

研究设计与关键结果

  • 研究类型:随机、开放标签、非劣效性试验,纳入两家ICU共225例患者(HFNC组113例,NIV组112例)进行意向性治疗分析。
  • 主要终点:HFNC组治疗失败率25.7%,NIV组14.3%,风险差11.38%(95%CI 0.25-21.20,P=0.033),超过9%非劣效界值。
  • 符合方案分析:HFNC组治疗失败28/110(25.5%),NIV组15/109(13.8%),风险差11.69%(95%CI 0.48-22.60)。
  • 次要终点:HFNC组插管率14.2%,高于NIV组5.4%(P=0.026);治疗切换率、ICU住院时间、住院时间及28天死亡率两组差异均无统计学意义(均P>0.05)。

证据类型、等级与局限

  • 证据类型:随机对照非劣效性试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:对于AECOPD合并急性中度高碳酸血症性呼吸衰竭患者,HFNC未显示非劣于NIV,作为初始呼吸支持时治疗失败发生率高于NIV。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Although cumulative studies have demonstrated a beneficial effect of high-flow nasal cannula oxygen (HFNC) in acute hypercapnic respiratory failure, randomized trials to compare HFNC with non-invasive ventilation (NIV) as initial treatment in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) patients with acute-moderate hypercapnic respiratory failure are limited. The aim of this randomized, open label, non-inferiority trial was to compare treatment failure rates between HFNC and NIV in such patients.

METHODS: Patients diagnosed with AECOPD with a baseline arterial blood gas pH between 7.25 and 7.35 and PaCO2 ≥ 50 mmHg admitted to two intensive care units (ICUs) at a large tertiary academic teaching hospital between March 2018 and December 2022 were randomly assigned to HFNC or NIV. The primary endpoint was the rate of treatment failure, defined as endotracheal intubation or a switch to the other study treatment modality. Secondary endpoints were rates of intubation or treatment change, blood gas values, vital signs at one, 12, and 48 h, 28-day mortality, as well as ICU and hospital lengths of stay.

RESULTS: 225 total patients (113 in the HFNC group and 112 in the NIV group) were included in the intention-to-treat analysis. The failure rate of the HFNC group was 25.7%, while the NIV group was 14.3%. The failure rate risk difference between the two groups was 11.38% (95% CI 0.25-21.20, P = 0.033), which was higher than the non-inferiority cut-off of 9%. In the per-protocol analysis, treatment failure occurred in 28 of 110 patients (25.5%) in the HFNC group and 15 of 109 patients (13.8%) in the NIV group (risk difference, 11.69%; 95% CI 0.48-22.60). The intubation rate in the HFNC group was higher than in the NIV group (14.2% vs 5.4%, P = 0.026). The treatment switch rate, ICU and hospital length of stay or 28-day mortality in the HFNC group were not statistically different from the NIV group (all P > 0.05).

CONCLUSION: HFNC was not shown to be non-inferior to NIV and resulted in a higher incidence of treatment failure than NIV when used as the initial respiratory support for AECOPD patients with acute-moderate hypercapnic respiratory failure.

TRIAL REGISTRATION: chictr.org (ChiCTR1800014553). Registered 21 January 2018, http://www.chictr.org.cn.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Tan D, Wang B, Cao P, et al. High flow nasal cannula oxygen therapy versus non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: a randomized controlled non-inferiority trial. Crit Care. 2024. PMID: 39026242. doi:10.1186/s13054-024-05040-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。